ReviewLeukemia2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
Review in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03601624 (Multicenter Study of Pomalidomide, Cyclophosphamide, and Dexamethasone in Relapsed Refractory Myeloma), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Study of Pomalidomide, Cyclophosphamide, and Dexamethasone in Relapsed Refractory Myeloma: Safety Profile in Mexican Population
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.ESMO open · 2022Guideline
- European Myeloma Network guidelines for the management of multiple myeloma-related complications.Haematologica · 2015Guideline
- Trial
- Trial
- Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.Haematologica · 2015Trial
- Activating RARβ to overcome immunomodulatory drug resistance in t(4;14) human myeloma.Leukemia · 2026Article
- Venous thromboembolism prophylaxis in multiple myeloma patients receiving immunomodulatory therapy: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2026Review
- In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma.Chirality · 2026Article
- Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.Journal for immunotherapy of cancer · 2026Article
- Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- Comprehensive Evaluation of 1H-Isoindole-1,3(2H)-Dione Derivatives: Pharmacokinetic Studies and Analgesic Potential in Various Pain Models.International journal of molecular sciences · 2025Article
- Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.Clinical hematology international · 2025Review
- Review
- Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.Therapeutic advances in medical oncology · 2024Article
- Quantification of Pomalidomide Using Conventional and Eco-Friendly Stability-Indicating HPTLC Assays: A Contrast of Validation Parameters.ACS omega · 2023Article
- Therapeutic strategies to enhance immune response induced by multiple myeloma cells.Frontiers in immunology · 2023Review
- Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma.Cancers · 2022Review
- Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.Therapeutic advances in hematology · 2022Review
- Towards design of drugs and delivery systems with the Martini coarse-grained model.QRB discovery · 2022Review
- Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, whereas dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopaenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism is provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.